Literature DB >> 9884100

Outcome criteria for lupus nephritis trials: a critical overview.

D T Boumpas1, J E Balow.   

Abstract

Lupus nephritis is an important cause of morbidity and mortality in patients with systemic lupus erythematosus. Traditional outcome criteria such as doubling of serum creatinine, end-stage renal disease and death have been used in controlled therapeutic trials, but are limited by their low incidence and the extended period of time required to reach them. More recently, discussions have focused on composite outcome measures, such as remission and relapse, as well as measures of health-related quality of life, general lupus activity and cumulative damage indexes. We review the strengths and weaknesses of several outcome criteria, and we propose criteria for both small pilot studies and large definitive trials.

Entities:  

Mesh:

Year:  1998        PMID: 9884100     DOI: 10.1191/096120398678920758

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  22 in total

Review 1.  Lupus and pregnancy: complex yet manageable.

Authors:  Josephine Patricia Dhar; Robert J Sokol
Journal:  Clin Med Res       Date:  2006-12

Review 2.  Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.

Authors:  Lin-Lin Liu; Yi Jiang; Li-Ning Wang; Li Yao; Zi-Long Li
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

3.  Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study.

Authors:  Jiwon Hwang; Hyung Jin Kim; Ji-Min Oh; Joong Kyong Ahn; Yoo Sun Lee; Jaejoon Lee; Yoon-Goo Kim; Woo-Sung Huh; Jinwon Seo; Eun-Mi Koh; Hoon-Suk Cha
Journal:  Rheumatol Int       Date:  2011-03-27       Impact factor: 2.631

Review 4.  [Systemic lupus erythematosus--activity and outcome].

Authors:  M Aringer; J Smolen
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

Review 5.  Treatment of proliferative lupus nephritis: a slowly changing landscape.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Nat Rev Nephrol       Date:  2010-12-21       Impact factor: 28.314

Review 6.  Pregnancy in systemic lupus erythematosus.

Authors:  C C Mok; R W Wong
Journal:  Postgrad Med J       Date:  2001-03       Impact factor: 2.401

7.  Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis.

Authors:  Sang-Seokg Seong; Chan-Bum Choi; Hye-Ryeon Yun; Yoon-Jeong Kim; Yoon-Kyoung Sung; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2007-10-09       Impact factor: 2.631

8.  Value of a complete or partial remission in severe lupus nephritis.

Authors:  Yiann E Chen; Stephen M Korbet; Robert S Katz; Melvin M Schwartz; Edmund J Lewis
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 8.237

9.  Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome).

Authors:  Meral Calguneri; Zeynep Ozbalkan; M Akif Ozturk; Sule Apras; A Ihsan Ertenli; Sedat Kiraz
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 2.980

10.  Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus.

Authors:  Zhenpeng Dai; Cameron J Turtle; Garrett C Booth; Stanley R Riddell; Theodore A Gooley; Anne M Stevens; Thomas Spies; Veronika Groh
Journal:  J Exp Med       Date:  2009-03-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.